News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Strong interim result in Phase I/IIa DIABECELL® trial

Living Cell Technologies Limited
Company Announcement

Strong interim results in Argentinian Phase I/IIa DIABECELL® trial

22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the results of an interim analysis of its Argentinian Phase I/IIa clinical trial for DIABECELL®, a breakthrough treatment for people with unstable type 1 diabetes.

The results clearly demonstrated a clinically significant reduction in HbA1c, insulin dose and unaware hypoglycaemia, with greater benefit being seen in the patient group receiving the higher dose of DIABECELL.

The trial, which is ongoing, involves eight patients split into two groups of four. Group one received two 5,000 IEQ/kg doses of DIABECELL (islet equivalents per kilogram of body weight). Group two received two 10,000 IEQ/kg doses of DIABECELL. In both groups, the second dose was implanted 12 weeks after the first. At the time of this interim analysis, group one patients were at 24 weeks follow up after the second transplant, and group two patients were at 12 weeks follow up after the second transplant.

In the second group of patients (those receiving the higher dose of two implants of 10,000 IEQ/kg) the most significant clinical benefits were:

• average insulin dose reduced by 20%
• a reduction of HbA1c from a pre-transplant average of 8.6% to an average of 6.7% at 12 weeks following the second implant
• up to 70% reduction in unaware hypoglycaemic events.

“Most type 1 diabetic patients who cannot attain reasonable control of their disease by conventional intensive insulin treatment would welcome the degree of control achieved with two doses of DIABECELL,” said Professor Bob Elliott, Chief Scientific and Medical Officer, LCT. “The reduction in both average daily insulin dose and HbA1c is clear demonstration of the positive effect of the DIABECELL transplant.”

DIABECELL is the first islet transplant treatment that does not require ongoing administration of debilitating immunosuppression drugs. DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.

“This interim analysis has been used to inform our 20 patient Phase IIb study, the start of which has also been announced today,” said Dr Andrea Grant, Chief Executive, LCT. “With each trial analysis we grow increasingly confident that DIABECELL will bring many benefits to patients with unstable type 1 diabetes, and we remain intently focused on reaching the market by 2016.”


– Ends –

For further information: www.lctglobal.com

About DIABECELL
Diabetes is usually treated with insulin replacement. A serious and potentially fatal complication associated with intensive insulin replacement therapy is unaware hypoglycaemia. Episodes of unaware hypoglycaemia occur when, without associated symptoms or warning, blood glucose levels drop suddenly. Some patients require significant time and resources from specialist healthcare professionals and have a poor prognosis: lower quality of life, more micro vascular and pregnancy complications and shortened life expectancy.
Treatment with DIABECELL® involves transplanting pig pancreatic islet cells into a patient’s abdomen to boost insulin production and help regulate blood glucose levels. The cells are encapsulated with IMMUPEL™ to prevent the immune system rejecting them as foreign. This proprietary technology ensures the cells can deliver their beneficial effects without the patient requiring immunosuppressant drugs.
DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50% interest.
For a summary of DIABECELL’s clinical trial programme please see the DIABECELL clinical trial update on LCT’s website www.lctglobal.com or DIABECELL clinical trial update.

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson’s disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Fringe Review: Rossum’s Universal Robots

Written in 1920 by Karel Capek in a newly independent Czechoslovakia, its prophetic tale of artificial intelligence, automata and human morality was initially a big hit, but it then vanished from view, in New Zealand at least, before being revived in Hamilton last year. More>>

SELECT FRINGE SHOWS:

Pictures Of Media: Call For Photographs For Reimagining Journalism

In August this year Freerange Press is launching its next big book. This time we are gathering the best writers and thinkers in the country to look at the changing media landscape in New Zealand. To illuminate and give voice to the writing we want to include around 25 excellent photos. We want these photos to document the different aspects of how journalism is made, how it used to be, and how it is changing. More>>

Safer Internet Day: Keeping Safe Online More Important Than Ever

Tuesday 9 February marks Safer Internet Day. Safer Internet Day is designed to create awareness about the importance of Internet safety and encourages positive use of technology - with a strong focus on young people. More>>

ALSO:

We Have The Technology: Zephyrometer Up And Moving

“The needle’s stoppers had to be repaired because of the extra impact caused by the balance not being correct. We also added an extra 300kgs counter-balance – made from zinc coated steel triangle plates. These adjustments will now stop it bending low over the road in high winds.” More>>

ALSO:

Waitangi Day: Treaty Of Waitangi - Found In Translation

To celebrate the Society of Translators and Interpreters's 30th anniversary, over 90 translators will work together to translate the English and Māori versions of the Treaty of Waitangi into 30 languages... More>>

ALSO:

Northland Development: Trust Applauds $4m Government Funding For Art Centre

Today's announcement of central government support, made by Minister of Economic Development Steven Joyce, provides a key step forward in funding for Whangarei’s Hundertwasser Art Centre & Wairau Maori Art Gallery. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news